Physician profile
Edward Lin
NPI 1326221334
$4,492.60
in general payments reported to CMS, 2019-2025
29 companies · $847 in 2025
The $847 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $311 · 2021: $881 · 2022: $374 · 2023: $65.49 · 2024: $1,009 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,012.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $450.14 | 2019-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $401.44 | 2019-2021 | |
| Amarin Pharma, INC. | $378.62 | 2019-2021 | |
| Astellas Pharma US INC | $329.09 | 2024-2025 | Veozah |
| Daiichi Sankyo INC. | $296.58 | 2019-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $245.02 | 2019-2022 | |
| Abbvie INC. | $164.18 | 2021-2025 | |
| Esperion Therapeutics, INC. | $156.31 | 2021-2024 | Nexletol |
| Exact Sciences Corporation | $138.53 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $105.80 | 2019-2021 | |
| Amgen INC. | $99.89 | 2019-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $94.19 | 2021-2022 | |
| Medtronic, INC. | $90.98 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.70 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $59.91 | 2023-2024 | Heplisav-B |
| Allergan, INC. | $59.47 | 2019-2020 | |
| Shire North American Group INC | $57.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.03 | 2019-2022 | |
| Abbott Laboratories | $33.32 | 2022 | |
| Medtronic USA, INC. | $27.46 | 2019 | |
| Lilly USA, LLC | $24.98 | 2019-2024 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $24.59 | 2020 | |
| Si-Bone, INC. | $19.62 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.13 | 2022 | |
| Adlon Therapeutics L.P. | $16.31 | 2021 | |
| Eisai INC. | $15.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.94 | 2021 | |
| Genentech USA, INC. | $14.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.